Benefits of Breast Cancer Index

Susan K. Boolbol, MD

Video Categories: PMO Interview with the Innovator Series: Volume 8

Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.
March 31, 2015

Beginnings of Personalized Medicine for Myeloma

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.

September 20, 2013

The Cost of Personalized Medicine

Jayson Slotnik discusses the cost structure of diagnostics and pharmaceuticals in personalized medicine